Skip to main content
. 2012 Apr 9;7(4):e34321. doi: 10.1371/journal.pone.0034321

Figure 3. Efficient commitment of hBMMSC-iPSCs into CD34+ progenitor cells by treatment with the defined factors.

Figure 3

CD34+ progenitor cells were identified by flow cytometry analysis in the groups. Differentiated hBMMSC-iPSCs treated with the factors produced about 20% proportion of CD34+ progenitor cells (A), higher than that of nearly 13% from hFib-iPSCs by parallel performance (B). However, the efficiency for the spontaneous differentiation groups was low. The proportion in hBMMSC-iPSCs treated with no factor was nearly 2% (C) and it was much lower in hFib-iPSCs of nearly 1% (D). The data demonstrated that the defined factors employed here efficiently improved the efficient differentiation of CD34+ progenitor cells from iPSCs, and iPSCs derived from hBMMSCs was more efficient to produce CD34+ progenitor cells than those derived from human fibroblasts. The enriched CD34+ progenitor cells were analyzed from hBMMSC-iPSC versus hFib-iPSC differentiation systems by flow cytometry (E-F). (G-J) Flow cytometry analysis demonstrated that the expression of Oct4 (G and I) and Sox2 (H and J) was down regulated at day 14 after the differentiation. (K) The chemically induced cells were separated into CD34+ and CD34- subsets and the former only had detectable CD34 transcripts.